April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA97
Academic Journal
Steroid resistance in ulcerative colitis (UC) presents a difficult clinical challenge, with few available therapeutic options other than colectomy. Basiliximab is a chimeric monoclonal antibody to the interleukin-2 receptors. This has potential as new treatment for this condition. The article presents a study of basiliximab treated patients with steroid resistant UC. The study revealed that treatment with basiliximab in combination with steroids achieved an improvement in 95% and remission in 70% of patients with moderate steroid resistant UC.


Related Articles

  • Surgery for ulcerative colitis in 1,000 patients. Ikkeuchi, Hiroki; Uchino, Motoi; Matsuoka, Hiroki; Bando, Toshihiro; Matsumoto, Takayuki; Tomita, Naohiro; Syoji, Yasutugu; Kusunoki, Masato; Yamamura, Takehira; Utsunomiya, Joji // International Journal of Colorectal Disease;Aug2010, Vol. 25 Issue 8, p959 

    Ileal pouch–anal anastomosis (IPAA) has become the standard treatment for patients with ulcerative colitis (UC) who ultimately require a colectomy. Herein, we report results of our 24-year experience with that surgical method at our hospital. Data were collected regarding surgical...

  • Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Kaplan, G. C. // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 3, p122 

    A review of the article "Decreasing colectomy rates for ulcerative colitis: A population-based time trend study," by G. G. Kaplan and colleagues, which appeared in the "American Journal of Gastroenterology" in the 2012 issue is presented.

  • Neutrophil-related immunoinflammatory disturbance in steroid-overdosed ulcerative colitis patients. Yoshiyama, Shigeyuki; Miki, Chikao; Okita, Yoshiki; Araki, Toshimitsu; Uchida, Keiichi; Kusunoki, Masato // Journal of Gastroenterology;2008, Vol. 43 Issue 10, p789 

    There is some evidence that large preoperative doses of steroids are a causative factor for postoperative higher morbidity in ulcerative colitis (UC) patients. This study aimed to assess steroid-related changes in functional profiles of neutrophils in UC patients to estimate the immunological...

  • Ulcerative Colitis.  // BioDrugs;2010 Supplement 1, Vol. 24, p34 

    No abstract available.

  • Infliximab to treat severe ulcerative colitis. Cury, Dídia Bisamra; Cury, Marcelo de Souza; Hemerly Elias, Geraldo Vinicius; Mizsputen, Sender Jankiel; Pravda, Jay // World Journal of Gastroenterology;4/14/2009, Vol. 15 Issue 14, p1771 

    A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. The patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. The disease...

  • Corticotropin/prednisone withdrawal.  // Reactions Weekly;4/21/2007, Issue 1148, p14 

    A case study conducted on two patients who developed steroid withdrawal syndrome with symptoms of fever and abdominal pain during withdrawal of corticotropin or prednisone is presented. A woman who had ulcerative colitis and had been receiving prednisone over 10 years was admitted for colectomy....

  • MANAGEMENT OF SPASTIC, IRRITABLE COLON, WITH A NOTE ON ULCERATIVE COLITIS. Rosenblum, Louis A. // American Journal of Gastroenterology;Apr1958, Vol. 29 Issue 4, p407 

    Studies the management of spastic, irritable colon with emphasis on ulcerative colitis. Material and methods; Use of a preparation containing scopolamine methyl bromide, guar gum and a fecal softener; Interpretation of the findings.

  • Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech // New England Journal of Medicine;8/16/2012, Vol. 367 Issue 7, p616 

    Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1...

  • Balsalazide: increasing the choice for patients with ulcerative colitis.  // Drugs & Therapy Perspectives;Oct2003, Vol. 19 Issue 10, p1 

    Balsalazide (Colazide®, Colazol®) is a recent addition to the aminosalicylate drugs used to treat ulcerative colitis. After cleavage by bacterial azo-reductases in the colon, the active moiety mesalazine (mesalamine or 5-aminosalicylic acid) and an inert carrier compound are released. Oral...


Read the Article


Sign out of this library

Other Topics